% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Theruvath:154632,
      author       = {J. Theruvath and E. Sotillo and C. W. Mount and C. M. Graef
                      and A. Delaidelli and S. Heitzeneder and L. Labanieh and S.
                      Dhingra and A. Leruste and R. G. Majzner and P. Xu and S.
                      Mueller and D. W. Yecies and M. A. Finetti and D. Williamson
                      and P. D. Johann$^*$ and M. Kool$^*$ and S. Pfister$^*$ and
                      M. Hasselblatt and M. C. Frühwald and O. Delattre and D.
                      Surdez and F. Bourdeaut and S. Puget and S. Zaidi and S. S.
                      Mitra and S. Cheshier and P. H. Sorensen and M. Monje and C.
                      L. Mackall},
      title        = {{L}ocoregionally administered {B}7-{H}3-targeted {CAR} {T}
                      cells for treatment of atypical teratoid/rhabdoid tumors.},
      journal      = {Nature medicine},
      volume       = {26},
      number       = {5},
      issn         = {1546-170X},
      address      = {New York, NY},
      publisher    = {Nature America Inc.},
      reportid     = {DKFZ-2020-00900},
      pages        = {712-719},
      year         = {2020},
      note         = {2020 May;26(5):712-719},
      abstract     = {Atypical teratoid/rhabdoid tumors (ATRTs) typically arise
                      in the central nervous system (CNS) of children under 3
                      years of age. Despite intensive multimodal therapy (surgery,
                      chemotherapy and, if age permits, radiotherapy), median
                      survival is 17 months1,2. We show that ATRTs robustly
                      express B7-H3/CD276 that does not result from the
                      inactivating mutations in SMARCB1 (refs. 3,4), which drive
                      oncogenesis in ATRT, but requires residual SWItch/Sucrose
                      Non-Fermentable (SWI/SNF) activity mediated by BRG1/SMARCA4.
                      Consistent with the embryonic origin of ATRT5,6, B7-H3 is
                      highly expressed on the prenatal, but not postnatal, brain.
                      B7-H3.BB.z-chimeric antigen receptor (CAR) T cells
                      administered intracerebroventricularly or intratumorally
                      mediate potent antitumor effects against cerebral ATRT
                      xenografts in mice, with faster kinetics, greater potency
                      and reduced systemic levels of inflammatory cytokines
                      compared to CAR T cells administered intravenously. CAR T
                      cells administered ICV also traffic from the CNS into the
                      periphery; following clearance of ATRT xenografts,
                      B7-H3.BB.z-CAR T cells administered
                      intracerebroventricularly or intravenously mediate
                      antigen-specific protection from tumor rechallenge, both in
                      the brain and periphery. These results identify B7-H3 as a
                      compelling therapeutic target for this largely incurable
                      pediatric tumor and demonstrate important advantages of
                      locoregional compared to systemic delivery of CAR T cells
                      for the treatment of CNS malignancies.},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32341579},
      doi          = {10.1038/s41591-020-0821-8},
      url          = {https://inrepo02.dkfz.de/record/154632},
}